Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478456 | 0.74 | MAPK14 (0.40) | MAPK14 | |
| SCHEMBL1849601 | 0.72 | BRAF (0.35) | MAPK14ALDH1A1 | |
| SCHEMBL1848102 | 0.71 | CYP11B1 (0.34) | MAPK14 | |
| SCHEMBL2477806 | 0.70 | ERN1 (0.38) | — | |
| SCHEMBL2478554 | 0.64 | CYP17A1 (0.37) | MPOMAPK14ALDH1A1HPGDHSD17B10 | |
| SCHEMBL2480280 | 0.64 | KMO (0.40) | MAPK14 | |
| SCHEMBL2477807 | 0.63 | LMNA (0.48) | TP53 | |
| SCHEMBL1846598 | 0.62 | MAPK14 (0.34) | MAPK14 | |
| SCHEMBL2481187 | 0.62 | GRM5 (0.39) | MAPK14HSD17B10 | |
| SCHEMBL2477335 | 0.62 | BRAF (0.47) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| EP-2373664-B1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| EP-2373664-B1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-10-20 | — | — | US | disclosed |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-10-20 | — | — | US | disclosed |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-10-20 | — | — | US | disclosed |
| EP-2373664-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010070060-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070060-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K19, MAP4K3, MAP3K15 | MPO 4542/4885MAPK14 60/4885ALDH1A1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.